Visceral adiposity

Research context

Visceral adipose tissue (VAT) — the intra-abdominal depot surrounding the viscera — is metabolically active in a pro-inflammatory direction, releasing more non-esterified fatty acids, TNF-α, IL-6 and resistin, and less adiponectin, than subcutaneous fat, and correlates independently with insulin resistance, T2D, cardiovascular disease and MASH even after adjusting for total body fat. Imaging (CT/MRI) is the accurate quantification standard — the L4-L5 plane on CT with thresholds of >100 cm² (men) / >80 cm² (women) defines high-risk visceral obesity — while waist circumference is a practical but imprecise proxy. Two pharmacological precedents exist: tesamorelin (a GHRH analogue) reduced VAT by ~17–20% on CT in the Falutz HIV-lipodystrophy trials, selectively sparing subcutaneous fat, and incretin/dual agonists preferentially reduce VAT over subcutaneous fat in DXA/MRI sub-studies of SURMOUNT, STEP and SUSTAIN.

Why this matters metabolically

Two distinct pharmacological mechanisms target VAT: the incretin-class effects on body weight (with disproportionate VAT loss, mechanistically consistent with the higher lipolytic sensitivity of visceral adipocytes and possible direct GIP-receptor effects on visceral adipose macrophages) and the GH-axis effects on body-fat distribution (tesamorelin in HIV-associated lipodystrophy). Epicardial adipose tissue — the VAT depot on the cardiac surface — directly inflames the myocardium and contributes to HFpEF, and both semaglutide and tirzepatide reduce it in imaging sub-studies.

FAQs

What is visceral adipose tissue and why is it metabolically significant?

Visceral adipose tissue (VAT) is the depot surrounding the abdominal organs, distinct from subcutaneous adipose tissue (SAT). VAT is metabolically active in a pro-inflammatory direction — releasing more non-esterified fatty acids, TNF-α, IL-6 and resistin, and less adiponectin, than SAT — and is independently associated with insulin resistance, T2D, cardiovascular disease, MASH and metabolic syndrome even after controlling for total body fat, making it a high-priority therapeutic target.

What did the tesamorelin HIV-lipodystrophy trials show?

The pivotal phase 3 trials by Falutz et al. (2007 and 2010) showed tesamorelin — a GHRH analogue — reduced visceral adipose tissue by approximately 17–20% on CT volumetry in HIV-infected adults with antiretroviral-associated lipodystrophy, selectively, without meaningful subcutaneous-fat effects. This provided the regulatory basis for FDA approval (Egrifta) and the first phase 3 evidence that a peptide could produce measurable VAT-selective reduction as a primary endpoint.

How does GLP-1 receptor agonism affect visceral versus subcutaneous fat?

DXA and MRI body-composition sub-studies from SURMOUNT, STEP and SUSTAIN consistently show that GLP-1 and dual GLP-1/GIP agonists preferentially reduce visceral over subcutaneous fat during the initial weight-loss phase — in SURMOUNT-1 DXA analyses, tirzepatide reduced visceral fat to a greater degree than subcutaneous fat as a proportion of total fat lost. This is consistent with the higher lipolytic sensitivity of visceral adipocytes and possible direct GIP-receptor effects on visceral adipose macrophages.

Is waist circumference a reliable proxy for visceral adipose tissue?

Waist circumference is the most practical VAT proxy but cannot distinguish visceral from subcutaneous abdominal fat and shows substantial inter-observer variability. CT and MRI provide the most accurate quantification; the L4-L5 level on CT is the standard measurement plane, with thresholds of >100 cm² (men) and >80 cm² (women) defining high-risk visceral obesity.

Why do epicardial and pericardial fat matter here?

Epicardial adipose tissue (EAT) is the VAT depot on the cardiac surface that directly contacts and inflames the adjacent myocardium, contributing to HFpEF, atrial fibrillation and coronary atherosclerosis. Semaglutide and tirzepatide both reduce EAT volume in imaging sub-studies, a mechanistic contributor to observed cardiac functional improvements.